Navigation Links
TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
Date:10/12/2008

NATICK, Mass. and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The two-year pooled ARRIVE data showed that the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes, with no incremental risk of myocardial infarction (MI) or stent thrombosis. Analysis of the data was presented by John M. Lasala, M.D., Ph.D., F.A.C.C., at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

"The ARRIVE diabetic subset data demonstrated that the TAXUS Stent mitigated the adverse effect of diabetes as a risk factor for restenosis and repeat procedures in the patients studied," said Dr. Lasala, Professor of Medicine, Washington University School of Medicine in St. Louis. "While the diabetic patients had more cardiac risk factors, comorbidity and higher mortality than non-diabetics, the rates of reintervention, MI and stent thrombosis in the ARRIVE 1 and 2 registries were similar in both groups, regardless of risk profile."

The pooled analysis included two-year data on 2,112 medication-requiring diabetic patients and 5,380 non-diabetic patients from the ARRIVE registry program. The population was further segmented into a higher-risk group(1) and a lower-risk group. Due to a significant increase in comorbid risk factors in patients with diabetes compared to non-diabetics, multivariate modeling and analysis was used to
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
2. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
3. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
4. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
5. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
6. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
7. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
10. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
(Date:12/24/2014)... 23, 2014   Assurex Health, a personalized ... healthcare providers for behavioral health and chronic pain ... million in equity financing from new and existing ... President and Chief Executive Officer. The ... of Assurex Health,s GeneSight ®  products.  ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 Today at the 2011 AHRA FUJIFILM Medical ... portable ultrasound market with the commercial availability of the ... point-of-care and mobile healthcare environments, the Fazone CB is ... images quickly and easily for on-the-go clinicians. ...
... 15, 2011 Emdeon Inc. (NYSE: EM ... cycle management and clinical information exchange solutions, today announced ... quicker-to-market option for electronic prescribing of controlled substances (EPCS). ... legally allowed to electronically transmit controlled substance prescriptions to ...
Cached Medicine Technology:Fujifilm Launches Ultrasound Product Line in U.S. 2Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach 2Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach 3
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on ... Pennsylvania for 2014. The awards program, created in 2000, ... kind in the country. The program is a public/private ... Community and Economic Development, the Pennsylvania State Council of ... Penn Business Journal. , Charlie Wilson, Vice ...
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... National Institutes of Health has awarded a four-year, $1.4 million ... recent discovery: After ischemic stroke the type caused by ... a normal protein that plays a positive role in ... "We knew thrombin leaked out during hemorrhagic strokes ...
... HealthDay Reporter , TUESDAY, Nov. 22 (HealthDay News) -- ... harbor almost as much danger as too much salt, researchers report. ... than 6,000 or 7,000 milligrams of sodium per day, said Dr. ... issue of the Journal of the American Medical Association . ...
... News) -- ,A new study says that regular consumption of ... levels of bisphenol A (BPA), which has been associated with ... added that the increase may be temporary and more research ... the lining of metal food and beverage cans, in polycarbonate ...
... of you inside like there,s another half of you, ... the real me, the logic part of me, and it,s ... study participant with anorexia nervosa. (Garrison, NY) People ... "authentic," self whether their illness is separate from or ...
... in German . As the "recycling plant" ... it is inhibited, the cell chokes on its own waste. ... the proteasome for their uncontrolled growth. Biochemists at the Technische ... a new class of drugs that attacks the proteasome in ...
... -- Although men have higher cancer mortality rates than ... for cancer, according to a study conducted by researchers ... at Sanoa Consulting LLC, Muscle Shoals, Ala., and the ... which was funded by the National Institute of Dental ...
Cached Medicine News:Health News:How Much Salt Is Best for the Heart? 2Health News:How Much Salt Is Best for the Heart? 3Health News:BPA Levels Spike After Eating Canned Soup: Study 2Health News:Anorexia nervosa study finds inner conflicts over the 'real' self that have treatment implications 2Health News:New class of drugs for the reversible inhibition of proteasomes 2Health News:New class of drugs for the reversible inhibition of proteasomes 3Health News:Moffitt Cancer Center researchers find men less willing to be screened for cancer 2
... has been carefully considered with both the practitioner ... the optimum viewing angle and the largest field ... for perfect focus where it is needed - ... This along with Keeler's wide angle light beam ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
... The Heine Beta 200S is ... with a combination of patented ... and a range of corrective ... dpt. in single diopter steps. ...
... The ophthalmoscope with superior aspherical optics. Includes ... and observation beam by means of the ... reflex (Gullstrand-principle). The Beta 200 allows you ... section of the retina even with a ...
Medicine Products: